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Background
Acute and Chronic Rhinosinusitis (ARS/CRS) have a
strong health- economic impact. It can be assumed that
10-15% of the US and EU population suffers from CRS.
The success of topical drug delivery to the sinuses -
principally desirable - is limited because the paranasal
cavities are virtually non-ventilated areas. An innovative
inhalation system (PARI SINUS) which provides a pul-
sating aerosol has been shown to improve the particle
deposition within the paranasal sinuses compared to an
inhalation without vibration. Patients’ acceptance of this
device and the clinical effects of the therapy have been
evaluated.
Method
In this multicentric, non-interventional, retrospective
survey, private ENT-specialists completed a 2-page-
questionnaire with data from patients who received
inhalation therapy with saline solution via the pulsating
aerosol. Most of the parameters were assessed on a 7-
point scale from -3 (very negative) to +3 (very positive).
Results
The data from 33 ARS patients (17 female (f), 16 male (m)
average age 39,3 ±18 and 48 CRS patients (29 f, 22 m,
average age 49,8 ±12) who received the treatment twice a
day (mean 2,05 ±0,92) were evaluated. The acceptance of
the therapy and the handling of the inhalation technique
were rated as +2,46 ±0,95 and +2,27 ±0,98 respectively.
The general effect on symptoms was valued +2,27 ±0,36
for ARS and +1,76 ±0,43 for CRS patients. The impact on
quality of life (QOL) was graded +2,39 ±0,84 for ARS and
+2,18 ±0,76 for CRS. The course of the disease +2,48
±0,81 (ARS) and +2,05 ±1,01 (CRS). For ARS patients the
therapy led to a reduction in the use of nasal steroids
(+1,42 ±1,26) and oral antibiotics (+1,63 ±1,31). CRS
patients also needed fewer nasal steroids (+1,19 ±1,19)
and oral antibiotics (+1,49 ±1,06). A decrease in sick leave
days was reported for both patient groups (ARS +1,70
±1,07, CRS +1,26 ±1,23).
Conclusions
Inhalation therapy for the paranasal sinuses via pulsating
aerosol is well accepted by ARS and CRS patients. Sub-
stantial symptom relief, improvement of QOL, lowering
of the need for oral antibiotics and nasal steroids as well
as the decline in sick leave days make this non-invasive
and painless therapy an interesting treatment option.
Further studies for ARS and CRS are desirable to inves-
tigate the full potential of this topical therapy option.
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